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Lprove cardiac surgical mortality? Although further investi-
gation is clearly indicated, now may be too soon to recom-
mend more aggressive use of calcium antagonists before
cardiac surgery.
For infections, proof of causality requires satisfaction of
the Koch postulates. For noninfectious causality, proof ul-
timately means a prospective, randomized study. Achieving
such studies requires funding, however, and funding for
clinical research in cardiac surgery is remarkably absent.
Why? First, the National Heart, Lung and Blood Institute
decided nearly 15 years ago to invest federal dollars into
basic research rather than clinical research. This decision
may have been wise in the long run, but it has definite
short-term consequences. Second, the cardiac surgical mar-
ket is too small to be worth the investment for most private
corporations, such as the pharmaceutical industry and the
medical device industry. Because neither of these two fund-
ing problems is likely to change soon, cardiac surgeons
must make the best of what we have. The onus will always
remain on the reader and the responsible investigator not to
confuse association and causation.
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